Animals were injected with PBS or bleomycin (Bleo), and bleomycin-injected animals treated with PBS, an isotype-matched control Ab (Intact), or an anti–PDCA-1 Ab (Depleted), as described in Supplemental Figure 2A. Animals were monitored for general health and skin lesions, and organs were harvested on day 28. (A) Representative photographs illustrate clinical features, including the hunched back appearance (h), submandibular erythema (e), piloerection (p), and alopecia (a), in bleomycin-injected mice. None of the PBS-injected mice had these lesions. (B and C) Each of the aforementioned features were given a score of 1, as described in Methods, and clinical severity scores derived for individual animals (n = 9, 9, 22, and 19 animals in PBS, bleomycin alone, bleomycin + control Ab, and bleomycin + anti–PDCA-1 Ab groups, respectively). (D–F) Lung sections stained with H&E were scored for the severity of lung disease. Representative photomicrographs and histology scores are shown (magnification, 10×). (G and H) Skin sections stained with H&E were analyzed for dermal thickness, as indicated by arrows in the representative photomicrographs (magnification, 4×). Results are shown as symbol plots, each symbol representing an animal, and/or as stack plots. Horizontal lines on symbol plots represent mean values. Each stack on stack plots represents proportion of animals with a clinical or histology score, as indicated by the legend on the right of panels. *P < 0.05, **P < 0.01, ***P <0.001 (1-way ANOVA with Newman-Keuls multiple comparisons test in B, E, and H; χ² test with Yates correction in C and F).